What Is C‑Peptide and How Is It Produced?

C‑peptide (connecting peptide) is a 31‑amino‑acid fragment that is cleaved from proinsulin during insulin maturation inside pancreatic beta cells. Proinsulin is synthesized in the rough endoplasmic reticulum, folded, and transported to the Golgi apparatus, where it is packaged into secretory granules. Within these granules, specific proteases cut proinsulin to release equimolar amounts of mature insulin and C‑peptide into the portal circulation. This equimolar secretion means that measuring C‑peptide provides a direct surrogate for endogenous insulin production.

Insulin is rapidly extracted by the liver (first‑pass clearance) and has a half‑life of only 4–6 minutes. C‑peptide, in contrast, undergoes minimal hepatic uptake and is cleared primarily by the kidneys, with a half‑life of 20–30 minutes. This longer half‑life results in more stable plasma concentrations and makes C‑peptide a more reliable marker for assessing beta cell secretory capacity, especially when blood samples are taken at non‑standardized times. For a detailed biochemical overview, see the seminal review on C‑peptide physiology.

Beyond its role as a marker, C‑peptide may possess intrinsic biological activity. Preclinical studies suggest it binds to specific receptors on endothelial cells, activates the Na+/H+ exchanger, and reduces oxidative stress and inflammation in microvascular tissues. These effects have sparked interest in C‑peptide as a potential therapeutic agent for diabetic complications, though large‑scale human trials are still needed. Understanding C‑peptide’s dual role – as both a diagnostic window and a possible effector molecule – enriches its clinical value.

The Role of C‑Peptide Testing in Diabetes Management

C‑peptide testing allows clinicians to move beyond simple glucose numbers and assess the underlying pancreatic function. Whether the patient has autoimmune type 1 diabetes, insulin‑resistant type 2, or a monogenic form like MODY, the C‑peptide level contextualizes the disease and directs therapy. The test is most informative when interpreted alongside the simultaneous blood glucose concentration.

Detecting Residual Beta Cell Function in Type 1 Diabetes

Type 1 diabetes results from autoimmune destruction of beta cells, but this process is rarely complete. Many individuals, particularly in the first 2–5 years after diagnosis, retain measurable residual insulin secretion – the “honeymoon” or partial remission phase. Stimulated C‑peptide levels above 0.2 nmol/L (approximately 0.6 ng/mL) are associated with several clinical benefits: lower HbA1c, reduced insulin requirements (often <0.5 U/kg/day), fewer episodes of severe hypoglycemia, and a lower risk of diabetic ketoacidosis.

Clinical trials for immunomodulatory therapies – such as teplizumab, alefacept, and rituximab – have used sustained C‑peptide secretion as a primary endpoint to demonstrate beta cell preservation. Routine C‑peptide testing can identify patients who might benefit from these emerging therapies or from less intensive insulin regimens. The American Diabetes Association’s Standards of Care acknowledge the role of C‑peptide in staging type 1 diabetes and guiding treatment.

Applications in Type 2 Diabetes

In type 2 diabetes, beta cell dysfunction and insulin resistance coexist in varying proportions. C‑peptide levels can span a wide range. A high C‑peptide in the setting of hyperglycemia indicates that the pancreas is still producing substantial insulin but peripheral tissues are resistant – the classic insulin‑resistant phenotype. Conversely, a low or inappropriately normal C‑peptide in a hyperglycemic patient with type 2 diabetes signals progressive beta cell failure, often necessitating insulin therapy.

Serial C‑peptide measurements can guide medication titration. For example, a patient with preserved C‑peptide may respond well to insulin secretagogues (sulfonylureas) or incretin‑based therapies (GLP‑1 receptor agonists, DPP‑4 inhibitors). As C‑peptide declines over years, the clinician can anticipate the need for basal insulin and adjust dosing earlier. This personalized approach helps avoid treatment failures that occur when beta cell reserve is overestimated.

Distinguishing Between Diabetes Types

When the diabetes etiology is uncertain – for instance, in a young adult who is not clearly overweight and has no autoantibodies – C‑peptide testing can be invaluable. Autoantibody tests (GAD65, IA‑2, ZnT8) are the gold standard for confirming autoimmune type 1 diabetes, but they can be negative in some cases, especially after years of disease. A low or undetectable stimulated C‑peptide strongly supports type 1 diabetes or a monogenic insulin‑deficient form, whereas a preserved or high level suggests type 2 or maturity‑onset diabetes of the young (MODY).

The combination of C‑peptide, autoantibodies, and clinical features (age, BMI, family history) improves diagnostic accuracy. Latent autoimmune diabetes in adults (LADA) often presents with a slowly progressive decline and intermediate C‑peptide levels; distinguishing LADA from type 2 is important because LADA patients may benefit from earlier insulin therapy. The CDC’s classification resources highlight the use of C‑peptide in atypical presentations to avoid misclassification.

Methodology of C‑Peptide Testing

C‑peptide can be measured in serum, plasma, or urine. Each method has specific indications, advantages, and limitations.

Serum C‑peptide: Fasting samples are most common, but stimulated tests provide a more robust assessment of beta cell reserve. The two most widely used stimulation protocols are the mixed‑meal tolerance test (MMTT) and the glucagon stimulation test. In the MMTT, the patient consumes a liquid meal (e.g., Boost or Ensure) and C‑peptide is measured at 0, 60, 90, and 120 minutes. In the glucagon test, 1 mg of glucagon is given intravenously or intramuscularly, and C‑peptide is measured at 0 and 6 minutes (and sometimes at 10 minutes). The MMTT is considered the gold standard for clinical trials because it more closely reflects physiological conditions.

Reference ranges for fasting C‑peptide are approximately 0.2–1.0 nmol/L (0.6–3.0 ng/mL), but these vary by assay and laboratory. Stimulated levels in healthy individuals typically exceed 1.0–1.5 nmol/L. In patients with renal impairment, C‑peptide levels can accumulate, so interpretation must account for estimated GFR.

Urine C‑peptide: A 24‑hour urine collection provides an integrated measure of C‑peptide excretion and is less affected by short‑term fluctuations. It can be useful when repeated blood sampling is impractical, such as in children or patients with poor venous access. The urine C‑peptide‑to‑creatinine ratio is sometimes used to adjust for renal function, though it is not as standardized as serum measurements.

Assay considerations: Modern two‑site immunometric assays (ELISA or chemiluminescence) have high specificity for C‑peptide and minimal cross‑reactivity with proinsulin. However, older radioimmunoassays may overestimate C‑peptide due to proinsulin interference. Hemolyzed samples can also produce spurious results. Laboratories should validate their assays and provide appropriate reference intervals for fasting, stimulated, and urine measurements.

Interpreting C‑Peptide Results: Clinical Scenarios

Correct interpretation requires simultaneous assessment of blood glucose. Without this context, a C‑peptide level is clinically ambiguous. The following scenarios illustrate typical patterns.

Low C‑Peptide with Hyperglycemia

This pattern indicates absolute insulin deficiency, most commonly due to autoimmune type 1 diabetes or long‑standing type 2 diabetes with beta cell exhaustion. In children or lean adults with acute onset of hyperglycemia and ketosis, a low C‑peptide virtually confirms type 1 diabetes. In patients with established type 2 diabetes, a low C‑peptide (<0.2 nmol/L fasting) suggests that oral agents are unlikely to be sufficient and that insulin therapy is warranted. For a practical guide on using C‑peptide in clinical practice, see the Endocrine Society’s evaluation of hypoglycemia guidelines.

High C‑Peptide with Hyperglycemia

This pattern is typical of insulin resistance. The pancreas is producing excessive insulin in an attempt to overcome peripheral resistance. Common causes include obesity, metabolic syndrome, early type 2 diabetes, and, rarely, insulin receptor defects (e.g., type A insulin resistance). Management focuses on improving insulin sensitivity through lifestyle modification, metformin, thiazolidinediones, and GLP‑1 receptor agonists. If hyperglycemia persists despite maximal therapy, consideration should be given to the possibility of evolving beta cell dysfunction – a decline in C‑peptide over time signals the need for insulin.

Low C‑Peptide with Hypoglycemia

In a hypoglycemic patient, a low C‑peptide level effectively excludes endogenous hyperinsulinemia. The differential diagnosis includes exogenous insulin administration (factitious or therapeutic), insulin‑induced hypoglycemia from insulin therapy, non‑insulin‑mediated causes (e.g., sulfonylureas do not cause low C‑peptide – they actually stimulate secretion). If insulin antibodies are present (insulin autoimmune syndrome), C‑peptide may be low or normal while total insulin is high; this is a rare but important exception.

High C‑Peptide with Hypoglycemia

This is the hallmark of endogenous hyperinsulinemia and strongly suggests an insulinoma – a pancreatic beta cell tumor. The autonomous secretion of insulin is accompanied by equimolar C‑peptide. A supervised 72‑hour fast with serial measurement of glucose, insulin, C‑peptide, and proinsulin is the diagnostic gold standard. In healthy individuals, C‑peptide suppresses to very low levels during hypoglycemia; in insulinoma, it remains inappropriately elevated. Other causes of endogenous hyperinsulinemia include congenital hyperinsulinism (in neonates) and post‑gastric bypass hypoglycemia (though here the C‑peptide may be less elevated).

Low C‑Peptide with Normoglycemia

This pattern may be seen in individuals who have undergone pancreatectomy (total or near‑total) or islet cell transplantation with graft failure. It is also present in some patients with long‑standing type 1 diabetes who retain minimal beta cell function insufficient to maintain normal glucose but still measurable. In such cases, exogenous insulin is required.

Clinical Benefits and Utility of C‑Peptide Testing

  • Assessment of residual beta cell function in type 1 diabetes: Identifies the honeymoon phase, predicts future insulin requirements, and evaluates response to immunomodulatory therapies. In research, a stimulated C‑peptide >0.2 nmol/L at 2 years is often considered a successful outcome.
  • Differentiation of diabetes subtypes: Helps distinguish type 1 from type 2, LADA, and monogenic forms (MODY, neonatal diabetes). A low C‑peptide with negative autoantibodies may indicate a monogenic cause, prompting genetic testing.
  • Guidance for treatment intensification in type 2 diabetes: A falling C‑peptide signals progressive beta cell failure and the need for earlier insulin initiation. Conversely, preserved C‑peptide supports continued use of oral agents.
  • Evaluation of hypoglycemia: C‑peptide is essential for distinguishing insulinoma from factitious hypoglycemia. It is also used in the workup of post‑bariatric hypoglycemia and congenital hyperinsulinism.
  • Monitoring after pancreatic or islet cell transplantation: A rising C‑peptide level indicates graft viability and function. A decline, especially if accompanied by hyperglycemia, suggests rejection or graft failure and may trigger immunosuppression adjustment.
  • Research endpoints: C‑peptide is the gold standard surrogate endpoint in trials of beta cell preservation and regeneration. Its use has accelerated the development of therapies for type 1 diabetes.

Limitations and Considerations

Despite its value, C‑peptide testing has several limitations. The most important is its dependence on renal function. In chronic kidney disease (CKD stages 3–5), C‑peptide clearance is reduced, leading to falsely elevated levels. A C‑peptide level should be interpreted with caution when eGFR is below 60 mL/min/1.73 m². In such cases, urine C‑peptide measurement or reliance on other markers may be necessary.

Assay variability is another challenge. Different commercial kits have different reference ranges, and results are not always interchangeable. Clinicians should use the reference interval provided by their local laboratory and be aware of the specific assay used. Proinsulin cross‑reactivity, while minimized in modern two‑site assays, can still occur in some settings (e.g., with certain insulin secretagogues that increase proinsulin secretion).

Age, sex, and body composition also affect C‑peptide levels. Older individuals tend to have lower levels, and C‑peptide correlates positively with BMI due to increased insulin secretion in obesity. Ideally, age‑ and BMI‑adjusted reference ranges would be used, but they are rarely available in routine practice. The requirement for stimulated testing in many clinical scenarios (e.g., confirming residual function) adds complexity and may not be feasible in busy primary care settings.

Patients receiving exogenous insulin may develop insulin antibodies that can interfere with some older C‑peptide immunoassays. This interference is generally avoided by using assays that do not cross‑react with insulin antibodies. In rare cases, such interference can lead to spuriously low results.

Emerging Research and Future Directions

Beyond its diagnostic use, C‑peptide is being investigated as a treatment for diabetic microvascular complications. Preclinical and early clinical studies suggest that C‑peptide replacement may improve nerve conduction velocity in diabetic neuropathy, reduce podocyte injury in nephropathy, and enhance retinal blood flow in early retinopathy. The proposed mechanisms include activation of the Na+/K+‑ATPase pump and endothelial nitric oxide synthase, leading to improved microcirculation and reduced oxidative stress. If ongoing trials confirm these benefits, C‑peptide could become an adjunct therapy for patients with diabetes who have low endogenous levels.

C‑peptide is also gaining attention as a biomarker in other conditions. In polycystic ovary syndrome (PCOS), fasting C‑peptide levels correlate with insulin resistance and may help stratify cardiovascular risk. In metabolic syndrome, C‑peptide adds prognostic information beyond glucose and insulin alone. With the rise of precision medicine, integrating C‑peptide with genetic risk scores and autoantibody profiles is enabling earlier and more accurate classification of diabetes subtypes. For example, in newborn screening programs, C‑peptide measured in dried blood spots can help identify neonates at risk for monogenic diabetes.

Technological integration is another frontier. Continuous glucose monitors (CGMs) and closed‑loop insulin delivery systems could potentially incorporate C‑peptide data to estimate residual beta cell function and adjust algorithms accordingly. A C‑peptide “bio‑sensor” that provides real‑time measurements would be a transformative tool, though such technology is still in early development.

Conclusion

C‑peptide testing remains a cornerstone of modern diabetes care, providing a direct assessment of endogenous insulin secretion that is essential for accurate diagnosis, treatment guidance, and monitoring of therapeutic interventions. While limitations related to renal function, assay variability, and the need for stimulated testing must be considered, the information gained from a properly interpreted C‑peptide level can dramatically improve patient outcomes. From differentiating type 1 from type 2 diabetes to diagnosing insulinoma and evaluating islet transplant viability, C‑peptide’s utility spans the full spectrum of hyper‑ and hypoglycemic disorders.

Clinicians should become familiar with both fasting and stimulated C‑peptide testing and incorporate it into their diagnostic algorithm when the diabetes subtype is uncertain or when hypoglycemia requires investigation. As research continues to uncover new roles for C‑peptide – as a biomarker, a therapeutic agent, and a component of personalized treatment algorithms – its importance in endocrinology and primary care will only grow.